Standard Textile begins marketing its FDA-cleared pressure ulcer-preventing bedding system

Ohio-based Standard Textile has begun marketing its DermaTherapy bedding system that was recently approved by the FDA to reduce the overall occurrence of pressure ulcers.

The bedding, which has silklike fibers to help regulate the patient's "microclimate"--a combination of heat, moisture, pressure, friction and shear--got the regulatory agency’s nod last month.

In a statement, the company said conventional hospital bedding often generates excessive moisture, friction and shear, as well as lint and airborne particles that are potentially hazardous to patients.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The system has been used in clinical trials in the U.S., with one medical center claiming it both saved $1.5 million while reducing the time patients stayed in the hospital partly because of a reduction of hospital-acquired pressure ulcers, the company said.

"Our system-wide conversion to DermaTherapy® bedding has dramatically improved the quality of care for our Cone Health patients and delivered significant savings for our healthcare system from the reduction of pressure ulcers," Annette Osborne, vice president of Nursing and Patient Services at Cone Health in Greensboro, NC, said in the statement.

The bedding system was developed in partnership between Standard Textile and Precision Fabrics Group.

Suggested Articles

The FDA warned healthcare providers about cybersecurity vulnerabilities within certain clinical information systems made by GE Healthcare.

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

As public fascination with at-home DNA tests begins to wane, 23andMe announced that it will lay off about 100 of its staff, according to CNBC.